Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
===========================================================================================================

* Howard L. Kaufman
* Robert H. I. Andtbacka
* Frances A. Collichio
* Michael Wolf
* Zhongyun Zhao
* Mark Shilkrut
* Igor Puzanov
* Merrick Ross